- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.02. | Sera Prognostics CFO verkauft Aktien im Wert von 27.090 US-Dollar | 1 | Investing.com Deutsch | ||
| 14.02. | Wissenschaftlicher Leiter von Sera Prognostics verkauft Aktien für 27.090 US-Dollar | 1 | Investing.com Deutsch | ||
| 11.02. | Sera Prognostics dips 5%, prices $50M offering | 2 | Seeking Alpha | ||
| 10.02. | Sera Prognostics announces proposed public offering | 2 | Seeking Alpha | ||
| 10.02. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 07.01. | SALT LAKE CITY - Sera Prognostics-Direktor verkauft Aktien im Wert von 769 US-Dollar | 1 | Investing.com Deutsch | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 64 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 06.11.24 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.24 | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 10.09.24 | Sera Prognostics CEO sells shares worth $189,893 | 1 | Investing.com | ||
| 07.08.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2024 Financial Results | 107 | PR Newswire | SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
| 08.05.24 | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2024 Financial Results | 215 | PR Newswire | SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
| 20.03.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial Results | 228 | PR Newswire | SALT LAKE CITY, March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,360 | -0,37 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
25.02.2025 / 09:45... ► Artikel lesen | |
| OCUGEN | 0,581 | +0,26 % | Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease | MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,490 | -0,12 % | Viking Therapeutics Aktie: Einholung von Informationen | Viking Therapeutics befindet sich an einem entscheidenden Punkt, während der Biotechsektor auf ein dynamisches Jahr zusteuert. Die Aktie des Unternehmens brach am Montag um 11,75 Prozent auf 24,49 Euro... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,660 | +6,40 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| SCORPIUS | 0,158 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,170 | +0,34 % | BioCryst stock holds $18 target, JMP bullish on trial results | ||
| VAXART | 0,460 | +2,04 % | Vaxart, Inc.: Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial | Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the... ► Artikel lesen | |
| REDHILL BIOPHARMA | 3,350 | 0,00 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IBIO | 6,490 | 0,00 % | iBio, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ARBUTUS BIOPHARMA | 3,292 | +0,73 % | Arbutus Biopharma Corporation: Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna | BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and... ► Artikel lesen | |
| MANNKIND | 4,900 | -0,33 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
| ALDEYRA | 5,886 | +1,90 % | Aldeyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CARDIFF ONCOLOGY | 3,800 | +4,40 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update | - Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer ("mCRC") clinical trial (CRDF-004) - - Priced oversubscribed $40 million... ► Artikel lesen | |
| TRAWS PHARMA | 4,490 | -100,00 % | Traws Pharma, Inc.: Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil | NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,408 | +5,97 % | Carisma Therapeutics Inc.: Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline | Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies
Development of CT-0525... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,080 (-1,90 %) liegt der Kurs bei 4,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.
